FDA extends review of Salix-Pharming’s HAE drug Ruconest to July
The marketing approval of Ruconest is for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). Ruconest (conestat alfa) is a recombinant human C1 esterase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.